Total Payments
$8,191
2024 Payments
$1,692
Companies
35
Transactions
469
Medicare Patients
1,176
Medicare Billing
$186,368
Payment Breakdown by Category
Food & Beverage$8,172 (99.8%)
Education$19.29 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,172 | 465 | 99.8% |
| Education | $19.29 | 4 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $1,155 | 66 | $0 (2024) |
| Alkermes, Inc. | $1,011 | 51 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $966.40 | 53 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $750.48 | 53 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $654.25 | 36 | $0 (2024) |
| Lundbeck LLC | $580.52 | 31 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $491.79 | 32 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $375.51 | 28 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $315.58 | 15 | $0 (2024) |
| IRONSHORE PHARMACEUTICALS INC. | $257.90 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,692 | 80 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($315.58) |
| 2023 | $1,195 | 62 | Alkermes, Inc. ($158.32) |
| 2022 | $757.06 | 41 | Janssen Pharmaceuticals, Inc ($177.47) |
| 2021 | $620.75 | 33 | Sunovion Pharmaceuticals Inc. ($154.62) |
| 2020 | $706.99 | 39 | Sunovion Pharmaceuticals Inc. ($135.51) |
| 2019 | $1,129 | 75 | Otsuka America Pharmaceutical, Inc. ($249.67) |
| 2018 | $1,097 | 74 | Otsuka America Pharmaceutical, Inc. ($169.41) |
| 2017 | $993.36 | 65 | Otsuka America Pharmaceutical, Inc. ($224.73) |
All Payment Transactions
469 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Lundbeck LLC | ABILIFY ASIMTUFII (Drug) | Food and Beverage | Cash or cash equivalent | $16.64 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Neuropsychiatry | ||||||
| 12/09/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $24.60 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Neurology | ||||||
| 11/21/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $11.51 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $26.90 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $31.13 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/11/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: Neuropsychiatry | ||||||
| 11/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $7.48 | General |
| Category: Central Nervous System | ||||||
| 11/01/2024 | Lundbeck LLC | ABILIFY ASIMTUFII (Drug) | Food and Beverage | Cash or cash equivalent | $20.52 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: PSYCHIATRY | ||||||
| 10/27/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.30 | General |
| Category: CNS | ||||||
| 10/21/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $9.13 | General |
| Category: Central Nervous System | ||||||
| 10/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $21.96 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/02/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Neurology | ||||||
| 09/26/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $32.60 | General |
| Category: CNS | ||||||
| 09/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: NEUROSCIENCE | ||||||
| 09/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.51 | General |
| Category: Neuropsychiatry | ||||||
| 09/12/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: PSYCHIATRY | ||||||
| 09/09/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $18.88 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 216 | 513 | $93,450 | $31,418 |
| 2022 | 9 | 255 | 635 | $104,625 | $35,885 |
| 2021 | 9 | 288 | 730 | $122,675 | $48,689 |
| 2020 | 8 | 417 | 1,247 | $177,150 | $70,376 |
Total Patients
1,176
Total Services
3,125
Medicare Billing
$186,368
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 47 | 121 | $20,900 | $6,888 | 33.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 28 | 163 | $22,775 | $5,862 | 25.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 39 | 43 | $12,825 | $4,937 | 38.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 53 | $11,600 | $4,477 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 74 | $11,100 | $4,103 | 37.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 19 | $6,175 | $2,082 | 33.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 25 | 27 | $4,050 | $1,554 | 38.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 13 | 13 | $4,025 | $1,514 | 37.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 58 | 174 | $26,100 | $9,073 | 34.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 77 | $15,400 | $5,827 | 37.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 31 | 198 | $24,750 | $5,649 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 71 | $10,650 | $3,744 | 35.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 27 | 27 | $7,425 | $3,440 | 46.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 24 | $7,800 | $3,394 | 43.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 27 | 35 | $5,250 | $1,892 | 36.0% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 16 | 16 | $4,000 | $1,647 | 41.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $3,250 | $1,219 | 37.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 59 | 66 | $18,400 | $9,879 | 53.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 53 | 149 | $22,350 | $8,511 | 38.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 46 | 96 | $19,200 | $7,848 | 40.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 99 | $14,850 | $6,303 | 42.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 37 | 193 | $24,125 | $5,829 | 24.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 60 | $10,500 | $4,630 | 44.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 32 | 38 | $5,700 | $2,145 | 37.6% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2021 | 17 | 17 | $4,250 | $1,944 | 45.7% |
About Dr. Rakesh Shah, MD
Dr. Rakesh Shah, MD is a Child & Adolescent Psychiatry healthcare provider based in Hopewell, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1942419692.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rakesh Shah, MD has received a total of $8,191 in payments from pharmaceutical and medical device companies, with $1,692 received in 2024. These payments were reported across 469 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($8,172).
As a Medicare-enrolled provider, Shah has provided services to 1,176 Medicare beneficiaries, totaling 3,125 services with total Medicare billing of $186,368. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Other Specialties Psychiatry
- Location Hopewell, VA
- Active Since 05/21/2007
- Last Updated 10/10/2013
- Taxonomy Code 2084P0804X
- Entity Type Individual
- NPI Number 1942419692
Products in Payments
- ABILIFY MAINTENA (Drug) $788.06
- ARISTADA (Drug) $755.12
- LATUDA (Drug) $750.48
- INGREZZA (Drug) $654.25
- REXULTI (Drug) $627.18
- CAPLYTA (Drug) $544.26
- INVEGA SUSTENNA (Drug) $427.53
- TRINTELLIX (Drug) $361.79
- SPRAVATO (Drug) $264.35
- ABILIFY ASIMTUFII (Drug) $227.64
- JORNAY PM (Drug) $216.99
- Aristada 441 mg (Drug) $204.39
- INVEGA TRINZA (Drug) $197.52
- VYVANSE (Drug) $160.60
- Austedo XR (Drug) $160.56
- Dyanavel XR (Drug) $159.59
- Azstarys (Drug) $145.73
- AUSTEDO (Drug) $142.58
- Trintellix (Drug) $130.33
- QELBREE (Drug) $114.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.